SCHEMBL2860455

SCHEMBL2860455

COc1ccc(Cn2c(=O)c3c(N)n(-c4cc(OC)ccc4C)nc3c3c(OC)cc(OC)cc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
THRB P10828 2/20 0.40
OPRK1 P41145 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.37
NPC1 O15118 2/20 0.37
RXFP1 Q9HBX9 2/20 0.37
DCTPP1 Q9H773 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PDE1A P54750 2/20 0.36
PDE1B Q01064 2/20 0.36
PDE1C Q14123 2/20 0.36
TYMS P04818 1/20 0.36
MAPT P10636 3/20 0.36
USP2 O75604 1/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861590 0.92 NPC1 (0.44) LMNATHRBOPRK1SMN1; SMN2NPC1
SCHEMBL2872737 0.90 OPRK1 (0.39) THRBOPRK1NPC1RXFP1DCTPP1
SCHEMBL2871608 0.87 KDM4E (0.42) LMNATHRBOPRK1NPC1RXFP1
SCHEMBL2861651 0.84 P2RX4 (0.48) LMNATHRBOPRK1SMN1; SMN2NPC1
SCHEMBL2866734 0.83 MAPT (0.42) LMNATHRBOPRK1SMN1; SMN2NPC1
SCHEMBL2861122 0.82 PDE1A (0.39) THRBOPRK1NPC1RXFP1MEN1
SCHEMBL2870490 0.82 NPC1 (0.43) LMNAOPRK1SMN1; SMN2NPC1MEN1
SCHEMBL2865359 0.82 ADORA3 (0.39) THRBSMN1; SMN2KDM4EMAPTPOLB
SCHEMBL2861317 0.79 P2RX4 (0.47) LMNASMN1; SMN2NPC1RXFP1MEN1
SCHEMBL2864991 0.79 NPC1 (0.44) LMNASMN1; SMN2NPC1RXFP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 LMNA 4123/4885THRB 825/4885OPRK1 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.